Redação Científica

Parte 1

XIV Encontro Regional da SBQ-Rio

Eliezer J. Barreiro

Professor

Universidade Federal do Rio de Janeiro

Laboratório de Avaliação e Síntese de Substâncias Bioativas

Instituto Nacional de Ciência e Tecnologia em Fármacos e Medicamentos

INCT-INOFAR

Projeto CNPq nº 573.564/2008-6 « » FAPERJ nº E-26/170.020/2008

Redação Científica

- Professor Eliezer J. Barreiro (UFRJ)
- *Ementa: Serão abordados os aspectos gerais sobre o papel da divulgação de resultados científicos; tipos de divulgação científica: artigos científicos, dissertações, teses, patentes; a importância do título; a construção do manuscrito; diferenças entre artigos e dissertações/teses; citações bibliográficas; cuidados com as palavras-chave; Bibliografia.*

www.uff.br/sbqrio

Redação Científica

Porquê publicar?

"publish OR perish"

"publish AND perish"

"…everything measured, detected, invented, or arrived at theoretically in the name of science must, as soon as possible, be made public – complete with details".

WE Russey

Quando publicar?

Aonde publicar?

O enfoque será na...

Química

Química

Química

Química

Química

Química

Química

Química

Química

Química

Química

Química

A publicação é o diálogo da ciência



Conhecimento científico

Idéia

Boa!

Pesquisa

Metodologia

Resultados

Válidos / validados

Publicação

Escrita

Aceitação

Comunidade científica

Conhecimento científico

Publicação

Divulgação

escrita

Revista científica

Revista divulgação

Pesquisador

X

Cientista

Publicar

- Quando se deve começar a pensar em escrever o manuscrito de nossa pesquisa?
- Como as novas tecnologias ajudam os cientistas a comunicar seu trabalho?
- Quantos rascunhos têm um manuscrito?
- Seus manuscritos passam por uma revisão interna?
- Os autores precisam estar pensando em algum marketing para seus artigos?
- O quanto se deve estar preocupado sobre o título e resumo dos artigos?

1 Novidade (originalidade)

2 Metodologia (inovadora)

3 Resultados (suficientes)

4 Apresentação impecável (redação)

"for their discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material"
Prêmio Nobel de Medicina e Fisiologia 1962

J. D. Watson & F. H. C. Crick

A Structure for

Deoxyribose

Nucleic Acid,

Nature **1953**, *171*, 737–738 .

Cavendish Laboratory of Cambridge University



Ligações de Hidrogênio entre Guanina (G) / Citosina (C) e Adenina (A) / Timidina (T)



O físico Crick & e o biólogo Watson



60 anos

DNA

1953-2013



3, 285 (1949).
[3] Von Arx, W. S., Woods Hole Papers in Phys. Oceanog. Meteor., 11 (3) (1950).
[4] Ekman, V. W., *Arkiv. Mat. Astron. Fysik.* (*Stockholm*), 2 (11) (1905).

MOLECULAR STRUCTURE OF NUCLEIC ACIDS

A Structure for Deoxyribose Nucleic Acid

WE wish to suggest a structure for the salt of deoxyribose nucleic acid (D.N.A.). This structure has novel features which are of considerable biological interest.

A structure for nucleic acid has already been proposed by Pauling and Corey[1]. They kindly made their manuscript available to us in advance of publication. Their model consists of three intertwined chains, with the phosphates near the fibre axis, and the bases on the outside. In our opinion, this structure is unsatisfactory for two reasons: (1) We believe that the material which gives the X-ray diagrams is the salt, not the free acid. Without the acidic hydrogen atoms it is not clear what forces would hold the structure together, especially as the negatively charged phosphates near the axis will repel each other. (2) Some of the van der Waals distances appear to be too small.

Another three-chain structure has also been suggested by Fraser (in the press). In his model the phosphates are on the outside and the bases on the inside, linked together by hydrogen bonds. This structure as described is rather ill-defined, and for this reason we shall not comment on it.

This figure is purely diagrammatic. The two ribbons symbolize the two phosphate—sugar chains, and the horizontal rods the pairs of bases holding the chains together. The vertical line marks the fibre axis

We wish to suggest a radically different structure for the salt of deoxyribose nucleic acid. This structure has two helical chains each coiled round the same axis (see diagram). We have made the usual chemical assumptions, namely, that each chain consists of phosphate diester groups joining β-D-deoxyribofuranose residues with 3′,5′ linkages. The two chains (but not their bases) are related by a dyad perpendicular to the fibre axis. Both chains follow right-handed helices, but owing to the dyad the sequences of the atoms in the two chains run in opposite directions. Each chain loosely resembles Furberg's[2] model No. 1; that is, the bases are on the inside of the helix and the phosphates on the outside. The configuration of the sugar and the atoms near it is close to Furberg's 'standard configuration', the sugar being roughly perpendicular to the attached base. There

from the fibre axis is 10 Å. As the phosphates are on the outside, cations have easy access to them.

The structure is an open one, and its water content is rather high. At lower water contents we would expect the bases to tilt so that the structure could become more compact.

The novel feature of the structure is the manner in which the two chains are held together by the purine and pyrimidine bases. The planes of the bases are perpendicular to the fibre axis. They are joined together in pairs, a single base from one chain being hydrogen-bonded to a single base from the other chain, so that the two lie side by side with identical z-co-ordinates. One of the pair must be a purine and the other a pyrimidine for bonding to occur. The hydrogen bonds are made as follows: purine position 1 to pyrimidine position 1; purine position 6 to pyrimidine position 6.

If it is assumed that the bases only occur in the structure in the most plausible tautomeric forms (that is, with the keto rather than the enol configurations) it is found that only specific pairs of bases can bond together. These pairs are: adenine (purine) with thymine (pyrimidine), and guanine (purine) with cytosine (pyrimidine).

In other words, if adenine forms one member of a pair, on either chain, then on these assumptions the other member must be thymine; similarly for guanine and cytosine. The sequence of bases on a single chain does not appear to be restricted in any way. However, if only specific pairs of bases can be formed, it follows that if the sequence of bases on one chain is given, then the sequence on the other chain is automatically determined.

It has been found experimentally[3,4] that the ratio of the amounts of adenine to thymine, and the ratio of guanine to cytosine, are always very close to unity for deoxyribose nucleic acid.

It is probably impossible to build this structure with a ribose sugar in place of the deoxyribose, as the extra oxygen atom would make too close a van der Waals contact.

The previously published X-ray data[5,6] on deoxyribose nucleic acid are insufficient for a rigorous test of our structure. So far as we can tell, it is roughly compatible with the experimental data, but it must be regarded as unproved until it has been checked against more exact results. Some of these are given in the following communications. We were not aware of the details of the results presented there when we devised our structure, which rests mainly though not entirely on published experimental data and stereochemical arguments.

It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material.

Full details of the structure, including the conditions assumed in building it, together with a set of co-ordinates for the atoms, will be published elsewhere.

We are much indebted to Dr. Jerry Donohue for constant advice and criticism, especially on interatomic distances. We have also been stimulated by a knowledge of the general nature of the unpublished experimental results and ideas of Dr. M. H. F. Wilkins, Dr. R. E. Franklin and their co-workers at

BBC News Sport Weather Travel Culture Auto

NEWS ENGLAND

Home UK Africa Asia Europe Latin America Mid-East US & Canada Business Health Sci/Envir

England Northern Ireland Scotland Wales UK Politics Education

11 April 2013 Last updated at 10:50 GMT

Share

DNA pioneer Francis Crick letter sells for $5.3m at New York auction



Crick wrote to his son in 1953 including a sketch of the DNA structure

A letter written by scientist Francis Crick describing his discovery of the double helix shape of DNA has been sold for $5.3m (£3.45m).

Related Stories

Source: http://www.bbc.co.uk/news/uk-england-22090344

Aonde publicar?





Qual é o sonho de consumo?

The Sequence of the Human Genome

J. Craig Venter, Mark D. Adams, Eugene W. Myers, Peter W. Li, Richard J. Mural, Granger G. Sutton, Hamilton O. Smith, Mark Yandell, Cheryl A. Evans, Robert A. Holt, Jeannine D. Gocayne, Peter Amanatides, Richard M. Ballew, Daniel H. Huson, Jennifer Russo Wortman, Qing Zhang, Chinnappa D. Kodira, Xiangqun H. Zheng, Lin Chen, Marian Skupski, Gangadharan Subramanian, Paul D. Thomas, Jinghui Zhang, George L. Gabor Miklos, Catherine Nelson, Samuel Broder, Andrew G. Clark, Joe Nadeau, Victor A. McKusick, Norton Zinder, Arnold J. Levine, Richard J. Roberts, Mel Simon, Carolyn Slayman, Michael Hunkapiller, Randall Bolanos, Arthur Delcher, Ian Dew, Daniel Fasulo, Michael Flanigan, Liliana Florea, Aaron Halpern, Sridhar Hannenhalli, Saul Kravitz, Samuel Levy, Clark Mobarry, Knut Reinert, Karin Remington, Jane Abu-Threideh, Ellen Beasley, Kendra Biddick, Vivien Bonazzi, Rhonda Brandon, Michele Cargill, Ishwar Chandramouliswaran, Rosane Charlab, Kabir Chaturvedi, Zuoming Deng, Valentina Di Francesco, Patrick Dunn, Karen Eilbeck, Carlos Evangelista, Andrei E. Gabrielian, Weiniu Gan, Wangmao Ge, Fangcheng Gong, Zhiping Gu, Ping Guan, Thomas J. Heiman, Maureen E. Higgins, Rui-Ru Ji, Zhaoxi Ke, Karen A. Ketchum, Zhongwu Lai, Yiding Lei, Zhenya Li, Jiayin Li, Yong Liang, Xiaoying Lin, Fu Lu, Gennady V. M[illegible]kulov, Natalia Milshina, Helen M. Moore, Ashwinikumar K Naik, Vaibhav A. Narayan, Beena Neelam, [illegible]ah Nusskern, Douglas B. Rusch, Steven Salzberg, Wei Shao, Bixiong Shue, Jingtao Su[illegible], [illegible]uan Wang, Aihui Wang, Xin Wang, Jian Wang, Ming-Hui Wei, Ron Wides, Chunlin Xiao, Chunl[illegible]ar[illegible] Alison Yao, Jane Ye, Ming Zhan, Weiqing Zhang, Hongyu Zhang, Qi Zhao, Liansheng Zhe[illegible] Fei Zhong, Wenyan Zhong, Shiaoping C. Zhu, Shaying Zhao, Dennis Gilbert, Suzanna Bau[illegible]er, Gene Spier, Christine Carter, Anibal Cravchik, Trevor Woodage, Feroze Ali, Huijin An, Ad[illegible]ve, Danita Baldwin, Holly Baden, Mary Barnstead, Ian Barrow, Karen Beeson, Dana Busam, A[illegible]Carver, Angela Center, Ming Lai Cheng, Liz Curry, Steve Danaher, Lionel Davenport, Raymond Des[illegible]ts, Susanne Dietz, Kristina Dodson, Lisa Doup, Steven Ferriera, Neha Garg, Andres G[illegible]n, Brit Hart, Jason Haynes, Charles Haynes, Cheryl Heiner, Suzanne Hladun, Damon Hostin, Ja[illegible]Houck, Timothy Howland, Chinyere Ibegwam, Jeffery Johnson, Francis Kalush, Lesley [illegible]e, Shas[illegible]Koduru, Amy Love, Felecia Mann, David May, Steven McCawley, Tina McIntosh, Ivy M[illegible], Mee Moy, Linda Moy, Brian Murphy, Keith Nelson, Cynthia Pfannkoch, Eric Pratts, Vini[illegible]Puri, [illegible]a Qureshi, Matthew Reardon, Robert Rodriguez, Yu-Hui Rogers, Deanna Romb[illegible] Bob [illegible]uhfel, Richard Scott, Cynthia Sitter, Michelle Smallwood, Erin Stewart, Renee Strong, E[illegible]Suh, Reginald Thomas, Ni Ni Tint, Sukyee Tse, Claire Vech, Gary Wang, Jeremy Wetter, Sher[illegible]Williams, Monica Williams, Sandra Windsor, Emily Winn-Deen, Keriellen Wolfe, Jayshree Zaveri, Karena Zaveri, Josep F. Abril, Roderic Guigó, Michael J. Campbell, Kimmen V. Sjolander, Brian Karlak, Anish Kejariwal, Huaiyu Mi, Betty Lazareva, Thomas Hatton, Apurva Narechania, Karen Diemer, Anushya Muruganujan, Nan Guo, Shinji Sato, Vineet Bafna, Sorin Istrail, Ross Lippert, Russell Schwartz, Brian Walenz, Shibu Yooseph, David Allen, Anand Basu, James Baxendale, Louis Blick, Marcelo Caminha, John Carnes-Stine, Parris Caulk, Yen-Hui Chiang, My Coyne, Carl Dahlke, Anne Deslattes Mays, Maria Dombroski, Michael Donnelly, Dale Ely, Shiva Esparham, Carl Fosler, Harold Gire, Stephen Glanowski, Kenneth Glasser, Anna Glodek, Mark Gorokhov, Ken Graham, Barry Gropman, Michael Harris, Jeremy Heil, Scott Henderson, Jeffrey Hoover, Donald Jennings, Catherine Jordan, James Jordan, John Kasha, Leonid Kagan, Cheryl Kraft, Alexander Levitsky, Mark Lewis, Xiangjun Liu, John Lopez, Daniel Ma, William Majoros, Joe McDaniel, Sean Murphy, Matthew Newman, Trung Nguyen, Ngoc Nguyen, Marc Nodell, Sue Pan, Jim Peck, Marshall Peterson, William Rowe, Robert Sanders, John Scott, Michael Simpson, Thomas Smith, Arlan Sprague, Timothy Stockwell, Russell Turner, Eli Venter, Mei Wang, Meiyuan Wen, David Wu, Mitchell Wu, Ashley Xia, Ali Zandieh, and Xiaohong Zhu

Science **2001** *291*, 1304-1351 [DOI: 10.1126/science.1058040]

O paper...



The Negative Results Journals

Everybody likes positive results. But the fact is that they are the less, especially when you talk about Science.

NEGATIVE RESULTS IN CHEMISTRY



The All Results Journals: Chem (**ISSN: 2172-4563**) focuses on recovering and publishing those experiments that either failed or led to "unexpected" results within all areas of Chemistry.

NEGATIVE RESULTS IN

- BIOLOGY
- CHEMISTRY
- NANOTECHNOLOGY
- PHYSICS

J CHEM
THE ALL RESULTS JOURNALS

REVIEW

Issue 1, Vol 4, 2013, 1-9

AuNPs-DNA non-covalent interactions: improve of some studies and new avenues of research from negative results.

David Alcantara[1*], Elia Grueso[2], P. M. Castillo[2], Rafael Prado-Gotor[2*]

1) Andalusian Center for Nanomedicine and Biotechnology (Bionand), Severo Ochoa, 35, 29590 Campanillas. Malaga, Spain; 2) Department of Physical-Chemistry, University of Seville, Profesor Garcia Gonzalez, S/N, 41012, Seville, Spain. E-mail: dalcantara@bionand.es; pradogotor@us.es. * To whom all correspondence should be addressed.

Keywords: *gold nanoparticles, DNA, biopolymers, thermodynamic, kinetics.*

Abstract: Due to their chemical stability, high biocompatibility, excellent structural, optical, magnetic and catalytic properties, gold nanoparticles (AuNPs) have been widely used as therapeutics, delivery agents and transfection vectors. Since successful therapy for curing cancer, and other genetic diseases, requires the transport of DNA into the cell by delivery vehicles, the effective complexation of the DNA is a subject of great interest. In this sense, increasing concerns have been raised in regards to the thermodynamics and kinetics of non-covalent interactions of AuNPs with DNA. Although insights have been gained into the effects of AuNPs on DNA systems, there is still much ground to be covered, particularly in respect to our knowledge of the binding modes, conformational changes, the salt effects and the aggregation properties of these systems. This review highlights recent progress in the study of the interactive effects of AuNPs with DNA and the factors that influence the kinetics and thermodynamic of this interaction.

Journal of Negative Results in BioMedicine

BioMed Central

Open Access

Commentary

A critique of the WHO TobReg's "Advisory Note" report entitled: "*Waterpipe tobacco smoking: health effects, research needs and recommended actions by regulators*"

Kamal Chaouachi*

Address: Researcher in Socio-Anthropology and Tobaccology, Consultant in Tobacco Control, 62, avenue Victor Hugo; 92100 Boulogne Billancourt, France

Email: Kamal Chaouachi* - kamcha@gmail.com

* Corresponding author

Published: 17 November 2006

Journal of Negative Results in BioMedicine 2006, **5**:17 doi:10.1186/1477-5751-5-17

Received: 19 July 2006
Accepted: 17 November 2006

This article is available from: http://www.jnrbm.com/content/5/1/17

The Journal of Irreproducible Results®

The Science Humor Magazine



Journal of Negative Results

— Ecology & Evolutionary Biology —

vol. 10: 1–5 • Helsinki, 2 January 2013

ISSN 1459-4625

http://www.jnr-eeb.org/

Journal of Pharmaceutical Negative Results

JOURNAL OF NEGATIVE RESULTS IN BIOMEDICINE



Publishing Tips

'8 reasons I accepted your article'

Journal editors reveal the top reasons a manuscript gets published

By Elizabeth Zwaaf | Posted on 15 January 2013

Peter Thrower, PhD

At Elsevier, it's the responsibility of every editor-in-chief to maintain and develop their journal's profile and reputation. The editor also has the final responsibility for content, ensuring that it meets the aims and scope of the journal and reflects changes in the field by presenting new and emerging research.

In September, Elsevier Connect published an article by Dr. Peter Thrower, Editor-in-Chief of *Carbon*, called "8 reasons I rejected your article." Because of the article's popularity, we followed up by asking five of our editors a related question: What are the top eight reasons you accept a paper? They all came up with similar reasons, which we present here along with their commentary.

The eight reasons are summed up by Dr. Torsten Pieper, Assistant Editor of the *Journal of Family Business Strategy*, and his colleague, Dr. Joseph Astrachan, Editor-in-Chief of the journal:

Torsten M. Pieper, PhD, is Assistant Professor at the Cox Family Enterprise Center, Coles College of Business, at Kennesaw State University in Georgia.

Joseph H. Astrachan, PhD, is Executive Director of the Cox Family Enterprise Center at Kennesaw State University and Professor of Management and Entrepreneurship.

1. It provides insight into an important issue – for example, by explaining a wide variance when numbers are spread out from the mean or expected value, or by shedding light on an unsolved problem that affects a lot of people.

2. The insight is useful to people who make decisions, particularly long-term organizational decisions or, in our particular field, family decisions.

3. The insight is used to develop a framework or theory, either a new theory or advancing an existing one.

4. The insight stimulates new, important questions.

5. The methods used to explore the issue are appropriate (for example, data collection and analysis of data).

6. The methods used are applied rigorously and explain why and how the data support the conclusions.

7. Connections to prior work in the field or from other fields are made and serve to make the article's arguments clear.

8. The article tells a good story, meaning it is well written and easy to understand, the arguments are logical and not internally contradictory.

O trabalho científico não termina na publicação!

❖ Aonde dá para publicar ou visando um periódico?

Sequência:

pesquisa ➡ redação ➡ publicação ➡ leitura ➡ (a)c(e)itação.

Impacto da publicação...

Respeitabilidade

Abrangência

(internacionalização!)

Aceitação

([auto-]crítica)

Atualmente se lê mais artigos científicos por ano

e

se gasta menos tempo por *artigo!*

Métrica da produtividade científica

MyResercherID (ISI) MyCitations (Google Scholar)

Autocitação

Redação científica

"objetiva" e *não* "subjetiva"

"intelectual" e *não* "emocional"

"estilo" e *não* "conversa"

"impessoal" e *não* "pessoal"

"formal" e *não* "coloquial"

"objetiva" e "subjetiva"

Início

Título

Objetivo, sempre!

No máximo 10 (+2) palavras!

Resumo

Livre. Cabe tudo, mas deve ser curto! 3 frases(?), 100 palavras

Molecules **2013**, *18*, 11683-11704; doi:10.3390/molecules181011683

OPEN ACCESS

molecules

ISSN 1420-3049

www.mdpi.com/journal/molecules

Article

Characterization of Amide Bond Conformers for a Novel Heterocyclic Template of *N*-acylhydrazone Derivatives

9

Alexandra Basilio Lopes [1,2], Eduardo Miguez [3], Arthur Eugen Kümmerle [4], Victor Marcos Rumjanek [4], Carlos Alberto Manssour Fraga [1,2,5,*] and Eliezer J. Barreiro [1,2,5,*]

Molecules **2012**, *17*, 14651-14672; doi:10.3390/molecules171214651

OPEN ACCESS

molecules

ISSN 1420-3049

www.mdpi.com/journal/molecules

Article

12

Synthesis and Pharmacological Evaluation of Novel Phenyl Sulfonamide Derivatives Designed as Modulators of Pulmonary Inflammatory Response

Maria Leticia de Castro Barbosa [1,2], Thiago José Figueira Ramos [3], Ana Carolina Santos de Arantes [3], Marco Aurélio Martins [3], Patrícia Machado Rodrigues e Silva [3], Eliezer J. Barreiro [1,2] and Lídia Moreira Lima [1,2,*]

Molecules **2012**, *17*, 14126-14145; doi:10.3390/molecules171214126

OPEN ACCESS

molecules

ISSN 1420-3049

www.mdpi.com/journal/molecules

Article

Design, Synthesis, Antinociceptive and Anti-inflammatory Activities of Novel Piroxicam Analogues

8

Amanda Silva de Miranda [1,2], Walfrido Bispo Júnior [3,4], Yolanda Karla Cupertino da Silva [3,4], Magna Suzana Alexandre-Moreira [3,4], Rosane de Paula Castro [5], José Ricardo Sabino [5], Luciano Morais Lião [6], Lídia Moreira Lima [1,2] and Eliezer J. Barreiro [1,2,*]

6

Oportunidades e Desafios para a Inovação em Fármacos: Agora ou Nunca!

Barreiro, E. J.;* Pinto, A. C.

Rev. Virtual Quim., **2013**, *5* (6), 1059-1074. Data de publicação na Web: 6 de setembro de 2013

http://www.uff.br/rvq

7

Dual β_2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD

Wen-Jun Shan [a], Ling Huang [a], Qi Zhou [a], Huai-Lei Jiang [a], Zong-Hua Luo [a], Ke-fang Lai [b,*], Xing-Shu Li [a,*]

European Journal of Pharmacology 702 (2013) 316–322

Cardiovascular pharmacology

A novel Ca^{2+} channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension

13

Sharlene Lopes Pereira [a], Arthur Eugen Kummerle [b], Carlos Alberto Manssour Fraga [a,c], Eliezer J Barreiro [a,c], Nazareth de Novaes Rocha [d], Emanuelle Baptista Ferraz [e], José Hamilton Matheus do Nascimento [e], Roberto Takashi Sudo [a,c], Gisele Zapata-Sudo [a,c,*]

European Journal of Medicinal Chemistry 62 (2013) 20–27

Original article

8

New oxidovanadium(IV) *N*-acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents

Julio Benítez [a], Aline Cavalcanti de Queiroz [b], Isabel Correia [c], Marina Amaral Alves [d,e], Magna S. Alexandre-Moreira [b], Eliezer J. Barreiro [d,e], Lidia Moreira Lima [d,e], Javier Varela [f], Mercedes González [f], Hugo Cerecetto [f], Virtudes Moreno [g], João Costa Pessoa [c], Dinorah Gambino [a,*]

European Journal of Medicinal Chemistry 62 (2013) 214–221

Original article

Biotransformation of LASSBio-579 and pharmacological evaluation of *p*-hydroxylated metabolite a *N*-phenylpiperazine antipsychotic lead compound

10

Tatiana F. Gomes [a], Thais E.T. Pompeu [b], Daniel A. Rodrigues [a], François Noël [b], Ricardo Menegatti [a], Carolina H. Andrade [a], José R. Sabino [c], Eric S. Gil [a], Teresa Dalla Costa [d], Andresa H. Betti [d], Camila B. Antonio [d], Stela M.K. Rates [d], Carlos A.M. Fraga [e], Eliezer J. Barreiro [e], Valéria de Oliveira [a,*]


Free acess
eliezer © 2013

Resumo (Abstracts)

IOP FTC

IOP PUBLISHING — JOURNAL OF PHYSICS A: MATHEMATICAL AND THEORETICAL

J. Phys. A: Math. Theor. **44** (2011) 492001 (5pp) — doi:10.1088/1751-8113/44/49/492001

FAST TRACK COMMUNICATION

Can apparent superluminal neutrino speeds be explained as a quantum weak measurement?

M V Berry[1], N Brunner[1], S Popescu[1] and P Shukla[2]

[1] H H Wills Physics Laboratory, Tyndall Avenue, Bristol BS8 1TL, UK
[2] Department of Physics, Indian Institute of Technology, Kharagpur, India

Received 12 October 2011, in final form 27 October 2011
Published 11 November 2011
Online at stacks.iop.org/JPhysA/44/492001

Abstract
Probably not.

Curto!

Resumo (Abstracts)

Bioorganic & Medicinal Chemistry Letters 22 (2012) 1523–1526

Contents lists available at SciVerse ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Dual β_2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD

Wen-Jun Shan [a], Ling Huang [a], Qi Zhou [a], Huai-Lei Jiang [a], Zong-Hua Luo [a], Ke-fang Lai [b,*], Xing-Shu Li [a,*]

[a] Institute of Drug Synthesis and Pharmaceutical Process, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China
[b] State Key Laboratory of Respiratory Diseases, Guangzhou Medical College, Guangzhou 510120, China

ARTICLE INFO

Article history:
Received 5 October 2011
Revised 26 December 2011
Accepted 6 January 2012
Available online 14 January 2012

Keywords:
Asthma and COPD
Bronchodilator
β_2-Adrenoceptor agonist
PDE4 inhibitor

ABSTRACT

We designed and synthesized a novel class of dual pharmacology bronchodilators targeting both β_2-adrenoceptor and PDE4 by applying a multivalent approach. The most potent dual pharmacology molecule, compound **29**, possessed good inhibitory activity on PDE4B2 (IC_{50} = 0.278 μM, which was more potent than phthalazinone, IC_{50} = 0.520 μM) and possessed excellent relaxant effects on tracheal rings precontracted by histamine (pEC_{50} = 9.3).

Graphical Abstracts

1 **Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors** Original Research Article

European Journal of Medicinal Chemistry, ***In Press, Accepted Manuscript***, *Available online 31 October 2013*

Maria Letícia de Castro Barbosa, Lídia Moreira Lima, Roberta Tesch, Carlos Mauricio R. Sant'Anna, Frank Totzke, Michael H.G. Kubbutat, Christoph Schächtele, Stefan A. Laufer, Eliezer J. Barreiro

Show preview | PDF (4280 K) | Supplementary content | Recommended articles | Related reference work articles

Graphical Abstract



marketing

Graphical abstracts





- Stable and storable common precursor
- Inexpensive starting materials and reagents
- Easy access to chiral auxiliary
- Enantiopure β^3-amino acids

Sobre o título

- Efeitos estereo-eletrônicos de grupos alquila na resposta biológica de substâncias bioativas,
- Efeito(s) de grupos alquila na resposta biológica de substâncias bioativas,
- Efeito(s) da metila na resposta biológica de substâncias bioativas,
- Efeitos da metila na atividade biológica,
- *Efeitos da metila em Química Medicinal*.

Volume 5, Número 2

Revista Virtual de Química
ISSN 1984-6835

Março-Abril 2013

As Longas Pernas do Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®; http://www.farmacia.ufrj.br/lassbio): Histórico e Perspectivas

Eliezer J. Barreiro

Universidade Federal do Rio de Janeiro, Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), CCS, Cidade Universitária, CP 68006, CEP 21944-910, Rio de Janeiro-RJ, Brasil.

* ejbarreiro@ccsdecania.ufrj.br

Recebido em 9 de janeiro de 2013. Aceito para publicação em 9 de janeiro de 2013



Redação científica

H. F. Ebel, C. Bliefert & W. E. Russey,

The Art of Scientific Writing

From students reports to Professional Publications





Redação Científica

W. E. Russey, H. F. Ebel & C. Bliefert

How to write a successful science thesis

The Concise Guide for Students

"publish OR perish"

"publish AND perish"

Redação Científica

Parte 2

XIV Encontro Regional da SBQ-Rio

Eliezer J. Barreiro

Professor

Universidade Federal do Rio de Janeiro

Laboratório de Avaliação e Síntese de Substâncias Bioativas

Instituto Nacional de Ciência e Tecnologia em Fármacos e Medicamentos

INCT-INOFAR

Projeto CNPq nº 573.564/2008-6 « » FAPERJ nº E-26/170.020/2008

Dissertação & Tese

Métodos & estilo

* Caderno de laboratório (eletrônico)
  Bibliografia (estado-da-arte)
* Primeiro rascunhão
  Estilo (primeira pessoa do plural)
* Parte técnica: linguagem atual (vernáculo)

Partes do trabalho (Tese ou Dissertação)

* Título
  Dedicatória & agradecimentos
  Índice (figuras etc)
  Resumo (Abstract)
  Introdução (estado-da-arte + definição do problema)
  [Objetivos]
* Resultados & Discussão (X Descrição)
  Conclusões (& Perspectivas)
  Parte experimental (refêrencias)
  Referências bibliográficas

Outras partes

Notas de roda-pé (footnotes)

* Tabelas

* Figuras
  Título, vinculação ao texto
  Esquemas (estruturas químicas: fonte, linhas etc)
  Diagramas, gráficos (títulos, fonte etc)
  Espectros Anexos (?)

* Cuidados especiais

Cronograma & prazos

* Revisão (idioma)

Midias

* Escolha do periódico

The most important sentence in any article is the first one.

—William Zinsser, *On Writing Well*

Métodos & estilo

* Caderno de laboratório (eletrônico)
  Bibliografia (estado-da-arte)
* Primeiro rascunhão
  Estilo (primeira pessoa do plural)
* Parte técnica: linguagem atual (vernáculo)

Partes do trabalho (Tese ou Dissertação)

* Título
  Dedicatória & agradecimentos
  Índice (figuras etc)
  Resumo (Abstract)
  Introdução (estado-da-arte + definição do problema)
  [Objetivos]
* Resultados & Discussão (X Descrição)
  Conclusões (& Perspectivas)
  Parte experimental (refêrencias)
  Referências bibliográficas

Caderno eletrônico de laboratório

OCTOBER 1, 2007 | VOLUME 85, NUMBER 40 | PP. 20

ELECTRONIC LAB NOTEBOOKS

A Collaborative Tool Settles Into Drug Research

Software and database vendors aim to supply researchers with tools to extract quality from quantity

Rick Mullin

Electronic laboratory notebooks (ELNs) have progressed from the periphery of pharmaceutical research three years ago to becoming central and ubiquitous tools among chemists in drug discovery and development. They are beginning to catch on with biologists and clinical researchers as well, according to vendors and users.

Research managers say the technology got a slow start due to scientists' reluctance to switch from standard paper notebooks to an electronic system that would put their work into a shared database. They also held off buying software in a field where many small developers were leapfrogging each other with frequent new-product releases.

Both situations have evolved. Laboratory managers say scientists now are finding that the software, which allows them to develop personal information workflows and rapidly access data, has more benefits than drawbacks. Researchers are also seeing the upside to sharing their work.

Caderno eletrônico de laboratório



Chemical Structure	
Chemical Taxonomy	Kingdom: Organic Class: Amino Acids Nitrogenous Compounds Family: Mammalian Metabolite Species: primary amine primary aliphatic amine (alkylamine) sulfonic acid Biofunction: Osmolyte; Essential amino acid; Protein component; Component of Taurine and hypotaurine metabolism Application: Not Available
Chemical Source	Endogenous
Molecular Weight	Monoisotopic: 125.01466 Average: 125.14688
Smiles (Isomeric)	NCCS(O)(=O)=O
Smiles (Canonical)	NCCS(O)(=O)=O
KEGG Compound ID	C00245
BioCyc ID	Not Available
BiGG ID	34373
Wikipedia ID	Taurine
METLIN ID	31
PubChem Compound ID	1123
PubChem Substance ID(s)	11113407 ; 90924 ; 855439 ; 828928 ; 11111855 ; 11407207 ; 821198 ; 828960 ; 7994998 ; 10503452 ; 7980729 ; 8027994 ; 3136598 ; 7852796 ; 7890685 ; 841390 ; 10323811 ; 3206 ; 820951 ; 7847115 ; 150971 ; 3544 ; 4666526 ; 8150965 ; 8145091 ; 8138146 ; 608224
ChEBI ID	15891
CAS Registry Number	107-35-7
InChI Identifier	InChI=1/C2H7NO3S/c3-1-2-7(4,5)6/h1-3H2,(H,4,5,6)
Synthesis Reference	Ishidate, M. et al., Chem. Pharm. Bull., 1954, 2, 275,



COMPOUND: C00245

Entry	C00245 Compound
Name	Taurine; 2-Aminoethanesulfonic acid; Aminoethylsulfonic acid
Formula	C2H7NO3S
Mass	125.0147
Structure	
Remark	Same as: D00047 D04538
Reaction	R01681 R01682 R01683 R01684 R01685 R01686 R01687 R02797 R03720 R03977 R04487 R05320 R05652 R07147
Pathway	PATH: map00120 Bile acid biosynthesis PATH: map00430 Taurine and hypotaurine metabolism PATH: map02010 ABC transporters - General PATH: map04080 Neuroactive ligand-receptor interaction
Enzyme	1.4.2.- 1.4.99.2 1.5.1.23 1.8.1.3 1.14.11.17 2.3.1.65 2.3.2.2 2.6.1.55 2.6.1.77 3.5.1.24 3.5.1.74 4.1.1.15 4.1.1.19
Other DBs	CAS: 107-35-7 PubChem: 3544 ChEBI: 15891 3DMET: B00069
Link DB	All DBs
KCF data	Show

=> Original format

Caderno **do** (de) laboratório

the case of a chemistry project one might find pages that begin:

Synthesis (Rearrangement, Isomerization, ...) of...
Characterization of...
Treatment of... with...

Nomenclatura oficial
Códigos cronológicos
Referências
OBS.
Dados espectroscópicos

Caderno do laboratório

- O caderno do laboratório pertence ao laboratório!
- Caderno (clássico) deve ter todas as folhas numeradas
- Não deve ter espaços (folhas) em branco;
- Não deve ser espiral, nem de fichário;
- Deve ser datado, sempre, diariamente;
- Se possível deve ser chancelado ou certificado;
- Deve-se ter cópia, atualizada, em outro local, seguro, do laboratório;

Critérios de rastreabilidade!

Quem não lê (com atenção) não escreve (bem)!

A redação científica tem de ser impecável!

Cuidado com o *desenho* das estrutruras químicas











Literatura & Bibliografia

- *Memória do grupo de pesquisas*
- Artigo de revisão/ autor(es) / SCI / key-words
- Web of Science et al.
- Banco bibliográfico: autor(es) / termos EndNote Web
- Tese/dissertação: bibliografia é crítica na introdução!

  e.g."De acordo com Fulano e colaboradores[4]" ou

  "Conforme descrito originalmente por Fulano e colaboradores[4]"

- Descrição de resultados X Discussão de resultados

EndNote: www.endnote.com/endemo.asp

Literatura & Bibliografia

- No caderno do laboratório, também (~~*tb*~~) cabe inclusões de referências:

  1. Prof. Beltrano, palestra ICB-UFSJM, data;
  2. Prof. Ciclam<u>o</u>, curso de “Teorias Falsas”, data (completa), local (instituição etc);
  3. VR Meyer, Practical HPLC, *ano*, Wiley, p.55;
  4. CJ Meyers, Lipids 1989, 72, 512 – descreve

otimização dos valores apresentados por A, B & C em TÍTULO, *J. Chem. Educ.* **1968**, *45*, 312-315) (??);

Sugestão de leitura

Organic Process Research & Development

EDITORIAL

pubs.acs.org/OPRD

Is Your Yield Truly Quantitative?

- *Rigor na descrição da parte experimental:*

Is Your Yield Truly Quantitative?

Org. Process Res. Dev. **2011**, *15*, 305

(DOI:10.1021/op2000404)

Organic Process Research & Development

Org. Process Res. Dev. **2011**, *15*, 305–305

Is Your Yield Truly Quantitative?

I am sure that all of us have experienced difficulty in obtaining the quoted yield in a paper describing an organic synthesis (Org. Process Res. Dev. (OPRD) excepted, of course, being often known as the Journal of Reproducible Results). A recent interesting report from Tomas Hudlicky, Brock University in Canada, in Synlett (2010, 18, 2701-2707) helps to explain why. He noticed that when comparing papers from 1955 to 1980 with those from 1980 to 2005, there was a much greater preponderance in yields of >95% in the modern papers, yet such high yields are rarely found in Organic Syntheses, where experiments are checked and independently produced.

Trevor Laird
Editor

Sugestão de leitura

On the Practical Limits of Determining Isolated Product Yields and Ratios of Stereoisomers: Reflections, Analysis, and Redemption[1]

Martina Wernerova, Tomas Hudlicky*

Department of Chemistry and the Centre for Biotechnology, Brock University, 500 Glenridge Avenue, St. Catharines, ON L2S 3A1, Canada
Fax 1(905)9844841; E-mail: thudlicky@brocku.ca

Received 4 August 2010

- Martina Wernerova &Tomas Hudlicky

On the Practical Limits of Determining Isolated Product Yields and Ratios of Stereoisomers: Reflections, Analysis, and Redemption[1]

Synlett **2010**, *2701–2707*

(DOI:10.1055/s-0030-1259018)

Tutoriais de redação de trabalho

- ACS George Whitesides
- ACS: tutoriais sobre “How writer a sci-paper”

http://pubs.acs.org/r/publishing101

Episode 1: How to Write a Paper to Communicate Your Research - Professor George Whitesides of Harvard University (600 papers) answers key questions about manuscript preparation.

Episode 2: Writing Your Cover Letter

Episode 3: Suggesting Potential Reviewers.

G. M. Whitesides, Whitesides’ group: writing a paper, *Adv. Mat.* **2004**, *16*, 1375–1377.

Episodes from the Series

View All Episodes

101 Publishing Your Research 101

Publishing Your Research 101 - Ep.1
How to Write a Paper to Communicate Your Research

Next Episode | View All YouTube Embed Code

Tweet 0 Curtir 32

Episode Summary

The first episode in our series is an interview with Professor George M. Whitesides from Harvard University who has published nearly 600 papers with ACS Publications, and over 1100 articles overall, and has served on the advisory boards of numerous peer-reviewed journals. He is dedicated to communicating

ok.com/sharer.php?u=http://pubs.acs.org/page/publish-research/index.html

More segments from the full interview

Videos

- Episode 1 (8:40)

Improving your writing skills (3:56)

About the Series

Publishing your Research 101: Practical Guidelines for Authors and Reviewers

The effective communication of scientific research is vital both to the scientific community and to a scientist's career. ACS Publications has launched the Publishing Your Research 101 video series to assist authors and reviewers in understanding and improving their experience with the processes of writing, submitting, editing, and reviewing manuscripts.
More >>

Please send your comments, suggestions, or questions to pub101@acs.org

Share the Series

ACS Network Facebook Twittter Email

Coming Soon

Episode 2: Writing Your Cover Letter will be released in June 2011. It features interviews with:

- *Inorganic Chemistry* Editor-in-Chief Richard Eisenberg, University of Rochester
- *Macromolecules* Editor-in-Chief TImothy P. Lodge, University of Minnesota
- *ACS Nano* Associate Editor Paula T. Hammond, Massachusetts Institute of Technology

Redação de Tese / Dissertação

Título
Preâmbulo / Prefácio / Agradecimentos / Dedicatória
Índice
Resumo / Abstracts
Lista de símbolos / abreviaturas / palavras-chaves
Introdução (1/3)
Objetivos / Justificativas
Resultados & Discussão
Conclusões / Perspectivas
Parte Experimental
Bibliografia / referências (/notas)
Apêndices / Anexos (mídia)

Obs:
Dificuldades: estilo / notas de roda-pé / ilustrações / padrões

Redação de Tese / Dissertação

Título
Preâmbulo / Prefácio / Agradecimentos / Dedicatória
Índice
Resumo / Abstracts
Lista de símbolos / abreviaturas / palavras-chaves
Introdução (1/3)
Objetivos / Justificativas
Resultados & Discussão
Conclusões / Perspectivas
Parte Experimental
Bibliografia / referências (/notas)
Apêndices / Anexos (mídia)

Obs:
Dificuldades: estilo / notas de roda-pé / ilustrações / padrões

Definir a Introdução

- Tema bem relacionado com o trabalho global;
- Contribuição para o estado-da-arte;
- Atualização de eventuais revisões anteriores;
- Organizar cronologicamente;
- Eleger as prioridades (análise crítica);
- Ler, re-ler, re-ler, re-ler, re-ler, re-ler, re-ler;
- Definir e aferir clareza dos sub-títulos;
- *Aproximar* dos objetivos.

CHEMICAL REVIEWS
Chem. Rev. 2011, 111, 5215-5246
REVIEW
dx.doi.org/10.1021/cr200060g
Impact Index = 40,05

The Methylation Effect in Medicinal Chemistry

E. J. Barreiro, A. E. Kümmerle and C. A. M. Fraga

CH_3

15 Da



LASSBio
Laboratório de Avaliação e Síntese de Substâncias Bioativas



Química Medicinal

Methyl Group

Biomacromolecules

CH/π interactions from the methyl group of timine. Conformational changes, wich could be involved on maintenance of life.

Micromolecules

The inductive eletronic effect of the methyl group is the responsible for the subtype receptors selectivity (H_2x H_1) on cimetidine



The stereoelectronic effects of the methyl group have great importance on biological events and are widely used by the Medicinal Chemistries in the development of new drugs.

Stereoelectronic Properties

MW = 15,03
MR = 5,65 cm³/mol
π hansch = 0,56
σ hammett = -0,17

Journal of Medicinal Chemistry

2012, *55*, 4489-450

Article

pubs.acs.org/jmc

Methyl Effects on Protein–Ligand Binding

Cheryl S. Leung, Siegfried S. F. Leung, Julian Tirado-Rives, and William L. Jorgensen*

Department of Chemistry, Yale University, New Haven, Connecticut 06520, United States

INTRODUCTION

The importance of methyl groups in modulating biological activity for small molecules is well documented.[1] Consistent with this, the most fundamental change in structure–activity studies is replacement of a hydrogen atom by a methyl group.

REFERENCES

(1) Barreiro, E. J.; Kümmerle, A. E.; Fraga, C. A. M. The Methylation Effect in Medicinal Chemistry. *Chem. Rev.* **2011**, *111*, 5215–5246.

Redação de Tese / Dissertação

Título
Preâmbulo / Prefácio / Agradecimentos / Dedicatória
Índice
Resumo / Abstracts
Lista de símbolos / abreviaturas / palavras-chaves
Introdução (1/3)
Objetivos (Justificativas)
Resultados & Discussão
Conclusões / Perspectivas
Parte Experimental
Bibliografia / referências (notas)
Apêndices / Anexos (mídia)

Dificuldades: estilo / notas de roda-pé / ilustrações / padrões

Resultados & *Discussão*

versus

Descrição de resultados

Dificuldades:

estilo / notas de roda-pé / ilustrações / padronização

Estado da arte / citações bibliográficas



Figura 1 - Efeito antinociceptivo de derivados *N*-acildrazônicos análogos ao piroxicam, administrados *p.o.* no ensaio de contorção abdominal induzida por ácido acético 1M em camondongos. Os dados apresentam média e o erro padrão da média (*p<0,05, **p<0,01 no teste *t*).

Redação de Tese / Dissertação

Título
Preâmbulo / Prefácio / Agradecimentos / Dedicatória
Índice
Resumo / Abstracts
Lista de símbolos / abreviaturas / palavras-chaves
Introdução (1/3)
Objetivos (Justificativas)
Resultados & Discussão
Conclusões / Perspectivas
Parte Experimental
Bibliografia / referências (notas)
Apêndices / Anexos (mídia)

Dificuldades: estilo / notas de roda-pé / ilustrações / padrões

- **Conclusões** X Conclusão
- *Distinto* de resumo;
- **Objetiva** & consistente (o título);
- Registro de fatos principais **X** cronologia;
- (Perspectivas podem estar inclusas);
- Não cabe referência bibliográfica;
- Deve ser objetivamente redigida;

Redação de Tese / Dissertação

Título
Preâmbulo / Prefácio / Agradecimentos / Dedicatória
Índice
Resumo / Abstracts
Lista de símbolos / abreviaturas / palavras-chaves
Introdução (1/3)
Objetivos / Justificativas
Resultados & Discussão
Conclusões / Perspectivas
Parte Experimental
Bibliografia / referências (/notas)
Apêndices / Anexos (mídia)*

---

* Incluir um CD-room na versão “hard”; planilha com estruturas químicas quando for o caso;

A defesa de tese...

- Apresentação # conferência!
- Slides “limpos”;
- Muita atenção à digitação (estruturas);
- Organização & tempo (fundamental);
- Não precisa ser idêntica à parte escrita;
- Atenção ao “efeito carnavalesco”;
- Agradecimentos (não deve ter dedicatória);

Concursos: memorial

- Mais do que o CV comentado!
- Histórico de sua trajetória (estudos, período);
- Motivações pessoais (episódios marcantes);
- Desempenho escolar;
- Estudos universitários: estágios, monitorias;
  - Graduação (início/fim)
  - Pós-graduação (orientador);
- Principais produções científicas (ilustre)
- Abordagem Cronológica.

Nature **2009**, *458*, 274

Supplanting the old media?

Science journalism is in decline; science blogging is growing fast. But can the one replace the other, asks **Geoff Brumfiel**.



RESEARCH ARTICLE

VIEWS SAVES

Discovery of Novel Orally Active Anti-Inflammatory *N*-Phenylpyrazolyl-*N*-Glycinyl-Hydrazone Derivatives That Inhibit TNF-α Production

Renata B. Lacerda, Leandro L. da Silva, Cleverton K. F. de Lima, Eduardo Miguez, Ana Luisa P. Miranda, Stefan A. Laufer, Eliezer J. Barreiro, Carlos A. M. Fraga

Published: Oct 08, 2012 • DOI: 10.1371/journal.pone.0046925

Article | About the Authors | Metrics | Comments | Related Content

Download PDF | Print | Share

Abstract

Herein, we describe the synthesis and pharmacological evaluation of novel *N*-phenylpyrazolyl-*N*-glycinyl-hydrazone derivatives that were designed as novel prototypes of p38 mitogen-activated protein kinase (MAPK) inhibitors. All of the novel synthesized compounds described in this study were evaluated for their in vitro capacity to inhibit tumor necrosis factor α (TNF-α production in cultured macrophages) and in vitro MAPK p38α inhibition. The two most active anti-TNF-α derivatives, (*E*)-2-(3-tert-butyl-1-phenyl-1*H*-pyrazol-5-ylamino) -*N*'-((4-(2-morpholinoethoxy)naphthalen-1-yl)methylene)acetohydrazide(4a) and (*E*)-2-(3-tert-butyl-1-phenyl-1*H*-pyrazol-5-ylamino)-N'-(4-chlorobenzylidene)acetohydrazide(4f), were evaluated to determine their *in vivo* anti-hyperalgesic profiles in carrageenan-induced thermal hypernociception model in rats. Both compounds showed anti-inflammatory and antinociceptive properties comparable to SB-203580 used as a standard drug, by oral route at a dose of 100 μmol/kg. This bioprofile is correlated with the ability of NAH derivatives (4a) and (4f) suppressing TNF-α levels *in vivo* by 57.3 and 55.8%, respectively.

Subject Areas

Isomers
Ethanol
Esters
Cytokines
Mixtures
NMR spectroscopy
Nuclear magnetic re...
High performance li...

Novo formato de paper!

RESEARCH ARTICLE

VIEWS | SAVES

Discovery of Novel Orally Active Anti-Inflammatory *N*-Phenylpyrazolyl-*N*-Glycinyl-Hydrazone Derivatives That Inhibit TNF-α Production

Renata B. Lacerda, Leandro L. da Silva, Cleverton K. F. de Lima, Eduardo Miguez, Ana Luisa P. Miranda, Stefan A. Laufer, Eliezer J. Barreiro, Carlos A. M. Fraga

Published: Oct 08, 2012 • DOI: 10.1371/journal.pone.0046925

Article | About the Authors | Metrics | Comments | Related Content

Download PDF | Print | Share

Viewed

Total Article Views

1,063

Oct 8, 2012 (publication date) through Nov 17, 2013*

	HTML Page Views	PDF Downloads	XML Downloads	Totals
PLOS	686	132	65	883
PMC	126	54	n.a.	180
Totals	812	186	65	1,063

22.91% of article views led to PDF downloads

2k

Subject Areas

- Isomers
- Ethanol
- Esters
- Cytokines
- Mixtures
- NMR spectroscopy

RESEARCH ARTICLE

VIEWS | SAVES

Discovery of Novel Orally Active Anti-Inflammatory *N*-Phenylpyrazolyl-*N*-Glycinyl-Hydrazone Derivatives That Inhibit TNF-α Production

Renata B. Lacerda, Leandro L. da Silva, Cleverton K. F. de Lima, Eduardo Miguez, Ana Luisa P. Miranda, Stefan A. Laufer, Eliezer J. Barreiro, Carlos A. M. Fraga

Published: Oct 08, 2012 • DOI: 10.1371/journal.pone.0046925

Related Authors

Renata B. Lacerda

Leandro L. da Silva

Cleverton K. F. de Lima

Eliezer J. Barreiro

Dear Prof. Barreiro,

Have you seen the Article of the Future?

The way we gather and digest information in our digital society has changed considerably. Yet, the layout and presentation of the published article has developed little in 350 years. Now, this is changing.
Article of the Future is our ongoing initiative to develop the scientific article with regard to three key areas: content, context, and presentation.

"...this seems like an ideal prototype of the 'article of the future'. It contains all that's normally found in a published article of today, but with immensely more functionality, interactivity and appeal."
Dr. Adam Radomsky, Concordia University, Canada

Introducing Elsevier's Article of the Future prototypes

The improved format will begin to be applied to all journals on SciVerse ScienceDirect towards the end of 2011. Before this, please review the prototypes online.

article of the future

ELSEVIER

Feedback welcome

follow us on twitter
#ElsevierAOTF

Sign up for alerts

Have you seen the Article of the Future?

Take a look at our prototypes and let us know what you think.

We have developed a new article format, which can be viewed through prototypes in seven disciplines, listed on the left hand menu. Experience our Article of the Future prototypes and let us know what you think by completing the survey included in each one.

About

Elsevier invests in platform innovation bringing together solutions like SciVerse ScienceDirect, SciVerse Scopus, web/third party content and SciTopics into one point of access: SciVerse. Now, through the Article of the Future project,

Open Access Video Journals

Cloud Video Journals

Cloud Journals brings world latest concept of open access video journal of research work at very ease and cost effective manner. We publish peer reviewed and open access online video journals in diverse areas of science, technology, medical, arts, humanities and management.

Cloud journals provides a very advance platform for researchers to make their research live and exemplify experimental visualization to the public. It helps them to demonstrate the work with their live camera shoot to all audience. By doing this authors get the rapid familiarity among their research communities within quick time span.

Cloud video journals facilitate your research by watching already done work to achieve the accuracy and betterment. You can see your applied techniques and methods n number of times and can reach at 100% accurate results.

Cloud Journals invites video research articles in all diverse areas of science, technology, medical, arts, humanities and management. We encourage all authors to publish their work with us as video journals.

Video Article Online Submission:

How to submit a video article?

Content of a Manuscript:

+ International Journal of Advanced Interdisciplinary Sciences

+ International Journal of Advanced Pharmaceutical Science and Technology

+ International Journal of Advanced Alternative Energy, Environment and Ecology

– International Journal of Advanced Biochemistry

International Journal of Advanced Biochemistry is peer-reviewed, open access online journal which welcomes original research articles as well as review articles in all areas of Biochemistry.

Navigation For

Authors
Editors
Reviewers
Societies
Institutions
Library
Special Issues
Open Access Policy
Publish With Us
Partners & Sponsors
Abstracting & Indexing

Looking For



Almoxarifado de idéias

Para se ter uma boa idéia, temos de estar “ligados”.

Para se ter uma boa idéia, é melhor ter várias idéias!

Banco de Teses

Patentes

Banco de substâncias

SciFinder®
The choice for chemistry research.™

Derwent World Patents Index

The world's most trusted source of patent information.

http://nihroadmap.nih.gov/molecularlibraries/index.asp

Favorites | "LASSBio-294" - PubChem BioAssay Results

NCBI | PubChem BioAssay

My NCBI [Sign In] [Register]

Search PubChem BioAssay for "LASSBio-294" Go Clear Save Search

Advanced Search | Preview/Index | History | Clipboard | Details

Display Summary Show 20 Sort By Send to

Tools: Links: Related BioAssays, Chemicals, Target, Literature, Other Links

All: 12 | NIH MLP: 0 | No Hold: 12 | On Hold: 0 | Summary: 0

Items 1 - 12 of 12 One page.

1: AID: 436510 Summary | Data Related BioAssays, Chemicals, Literature

Vasorelaxant activity in endothelium-intact Wistar rat thoracic aortic ring assessed as complete inhibition of phenylephrine-induced contraction at 20 uM in intact endothelium

Source: ChEMBL

Compound BioActivity: Active: 1, Tested: 1



CHEMBL572382

Description: Title: Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. Abstract: In... more

2: AID: 436509 Summary | Data Related BioAssays, Chemicals, Literature

Vasorelaxant activity in endothelium-denuded Wistar rat thoracic aortic ring assessed as inhibition of phenylephrine-induced contraction at 200 uM

Source: ChEMBL

Selected BioAssays | BioAssay Count

- BioActivity
  - Active Compounds 1
- Related BioAssays
- Depositor Category
  - Literature Extraction 12

Recent activity

Turn Off Clear

"LASSBio-294" (12) PubChem BioAssay

"LASSBio-294" (0) PubChem Compound

"LASSBio-294" (0) PubChem Substance

» See more...

Redação de Projetos

PROJETO (FAPERJ, 2002)

Planejamento, Síntese e Avaliação Farmaacológica de Novos Derivados 1,3,4-Tiadiazólicos, Candidatos a Inibidores de PGHS-2

Dr Eliezer J. Barreiro
Professor Titular - UFRJ

Preâmbulo

A recente descoberta de uma segunda isoforma da enzima prostaglandina-H sintetase, *i.e.* PGHS-2 ou COX-2, antecipou a possibilidade do desenvolvimento de inibidores seletivos representando agentes antiinflamatórios não esteroidais (NSAI) de segunda geração, úteis para o tratamento de quadros inflamatórios crônicos, sem efeitos gastro-irritantes típicos das agentes clássicos. Em prosseguimento aos esforços de pesquisa que o LASSBio vêm desenvolvendo nesta área e no âmbito de uma linha de pesquisas que visa o planejamento, a síntese e a avaliação farmacológica de novos inibidores enzimáticos seletivos, estruturalmente desenhados a partir de modelo topográfico 3D do sítio-ativo da PGHS-2, propomos, neste projeto, uma nova classe de compostos derivados do núcleo 1,3,4-tiadiazólico funcionalizado, como prováveis candidatos a inibidores seletivos de PGHS-2. Os novos compostos propostos possuem, em teoria, os requisitos estruturais mínimos para apresentarem a atividade pretendida e representarão novo padrão molecular de inibidores seletivos de PGHS-2.

Redação de Projetos

DOCUMENTO CONFIDENCIAL (CIRCULAÇÃO RESTRITA)
ESTE DOCUMENTO É DESTINADO EXCLUSIVAMENTE À FAPERJ E CONTÉM INFORMAÇÕES PRIVILEGIADAS, CONFIDENCIAIS E QUE NÃO DEVEM SER REVELADAS.

FAPERJ

Edital 29- 2008 – Cientista do Nosso Estado

Projeto:

Desenho estrutural, síntese e bioavaliação de novos candidatos a compostos-protótipos de novos fármacos simbióticos

(Parte 3: antiinflamatórios).

Coordenador: Prof. Dr. Eliezer J. Barreiro
LASSBio, Faculdade de Farmácia
Universidade Federal do Rio de Janeiro

Preâmbulo:

Esta solicitação trata do projeto "**Desenho estrutural, síntese e bioavaliação de novos candidatos a compostos-protótipos de novos fármacos simbióticos (Parte 3: antiinflamatórios)** situado no âmbito da **Química Medicinal**. Está composto por dois projetos específicos, a saber: a) "**Desenho estrutural, síntese e bioavaliação das propriedades antiinflamatórias de novos derivados *N*-acilidrazônicos: nova série 4-fenil-2-metilpirimidinila**"; b)"**Otimização de LASSBio-998, novo composto-protótipo antiinflamatório inibidor de proteína quinase ativada por mitógeno p38 (MAPK p38)**". O projeto visa dar seqüência aos esforços de pesquisa científica que vimos realizando no **Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®)** da **Universidade Federal do Rio de Janeiro** objetivando a descoberta de novos compostos protótipos candidatos a fármacos antiinflamatórios tratando pois da inovação radical e representa uma continuação do projeto E-26/152.529/2006 "Planejamento, síntese e avaliação farmacológica de candidato a compostos-protótipos de novos fármacos simbióticos – Parte 2", que o solicitante é beneficiário até 31 de dezembro de 2008.[1]

INCT-INOFAR

Ministério da Ciência e Tecnologia - MCT
Conselho Nacional de Desenvolvimento Científico – CNPq

Edital 15/2008

PROPOSTA DE INSTITUTO NACIONAL DE CIÊNCIA E TECNOLOGIA

INOVAÇÃO E DESENVOLVIMENTO DE FÁRMACOS E MEDICAMENTOS INCT-INOFAR

(Demanda Induzida SAÚDE
Fármacos e Medicamentos)

Faixa B

Coordenador: Eliezer J. Barreiro
Professor Titular

Universidade Federal do Rio de Janeiro

Setembro 2008

Preâmbulo:

O medicamento é instrumento essencial à correção, preservação, manutenção e promoção da Saúde. O acesso ao medicamento representa importante fator de inclusão social e expressão de cidadania e depende da disponibilidade do fármaco – princípio ativo contido no medicamento - em sua predominância, no arsenal terapêutico contemporâneo, composto por substâncias orgânicas de origem sintética.[1] A proposta de Instituto Nacional de Ciência e Tecnologia Inovação e Desenvolvimento em Fármacos e Medicamentos (INCT-INOFAR) se enquadra na área da Saúde,[2] como proposta de demanda induzida, especificamente em Fármacos e Medicamentos, tendo como metas articular, organizar e consolidar as competências nacionais existentes no País e situadas nos diferentes estágios da cadeia de inovação em fármacos e medicamentos, a exemplo do **Instituto do Milênio Inovação e Desenvolvimento em Fármacos e Medicamentos (IM-INOFAR**, www.farmacia.ufrj.br/im-inofar Proc. CNPq 420.015/05-1), projeto inspirador desta proposta e em vias de conclusão. Esta proposta pretende dar continuidade aos esforços de pesquisa realizados naquele Instituto e avançar na cadeia de inovação em fármacos e medicamentos. Desta feita, o **INCT-INOFAR** tem como objetivos e metas ampliar os expressivos resultados obtidos em âmbito do **IM-INOFAR**, que lograram na descoberta de compostos-protótipos, candidatos a novos fármacos antiinflamatórios e antiasmáticos,[3,4] viabilizando a conclusão de seus ensaios pré-clínicos.

[1] F. Chast, "A history of drug discovery" em "The Practice of Medicinal Chemistry" 3ª edição, C-G Wermuth, Editor, Academic Press, 2008, p. 1-62.
[2] Plano de Ação 2007-2010: Ciência, Tecnologia e Inovação para o desenvolvimento Nacional (PACTI),

Redação de Projetos: *Título!*

- Estudo fitobotânico da Família Apocinácea,
- Estudo fitobotânico da Família Apocinácea brasileira,
- Estudo fitoquímico de Apocinacéas brasileiras,

- Limitações? Objetividade nas informações!
- Objetividade? Principal característica: foco!
- Projetos podem ser re-apresentados! Treine!
- Use sempre o corretor ortográfica; revise!

A questão ética



F I M